吡柔比星联合地塞米松及沙利度胺治疗多发性骨髓瘤的效果观察

Effect Observation of Pirarubicin Combined with Dexamethasone and Thalidomide in Treatment of Multiple Myeloma

目的:探讨吡柔比星联合地塞米松及沙利度胺治疗多发性骨髓瘤的效果。方法:选取2020年1月-2023年8月郴州市第一人民医院收治的40例多发性骨髓瘤患者作为研究对象,以随机数字表法分为研究组与对照组,各20例。研究组2例失访,2例因更换治疗方案退组;对照组4例失访,2例因更换治疗方案退组;最终研究组纳入16例患者,对照组纳入14例患者。对照组应用地塞米松及沙利度胺治疗,研究组在对照组基础上应用吡柔比星治疗。比较两组血液指标、临床疗效以及不良反应发生情况。结果:治疗前,两组血红蛋白、白蛋白、球蛋白、血小板计数水平比较,差异无统计学意义(P>0.05);治疗后,两组血红蛋白、血小板计数水平均高于治疗前,且研究组高于对照组,两组白蛋白、球蛋白水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05)。研究组治疗总有效率高于对照组,差异有统计学意义(P=0.011)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论:吡柔比星联合地塞米松及沙利度胺治疗多发性骨髓瘤的效果显著,能够改善患者血液指标,且不会增加不良反应。

Objective:To explore the effect of pirarubicin combined with dexamethasone and thalidomide in the treatment of multiple myeloma.Methods:Forty patients with multiple myeloma admitted to Chenzhou No.1 People's Hospital from January 2020 to August 2023 were selected as the study subjects.They were divided into a study group and a control group according to random number table method,with 20 cases in each group.In the study group,two cases were lost to follow-up,and two cases were withdrawn due to changing treatment plans;in the control group,4 cases were lost to follow-up,and 2 cases were withdrawn due to changing treatment plans;finally the study group included 16 patients,while the control group included 14 patients.The control group was treated with dexamethasone and thalidomide,while the study group was treated with pirarubicin on the basis of control group.The blood indicators,clinical efficacy,and incidence of adverse reactions were compared between two groups.Results:Before treatment,there was no statistically significant difference in the levels of hemoglobin,albumin,globulin,and platelet counts between the two groups(P>0.05);After treatment,the levels of hemoglobin and platelet counts in two groups were higher than those before treatment,and the levels in the study group were higher than those in the control group.The levels of albumin and globulin in two groups were lower than those before treatment,and the levels in the study group were lower than those in the control group,with a statistically significant difference(P<0.05).The total effective rate of treatment in the study group was higher than that in the control group,and the difference was statistically significant(P=0.011).There was no significant difference in total incidence of adverse reactions between the two groups,and the difference was not statistically significant(P>0.05).Conclusion:The combination of pirarubicin,dexamethasone,and thalidomide has a significant effect in the treatment of multiple myeloma,which can improve patient's blood indicators and will not increase adverse reactions.